Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Additionally, the company’s commercial strategy to ensure broad access, including discussions with Integrated Delivery Networks (IDNs) and payers, positions Vertex favorably in the market ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Trinasolar has recently reached a significant milestone, delivering more than 1 GW of its Vertex N 720W series modules to the ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and raises full-year guidance, while navigating challenges ...

CREC will receive delivery of Trinasolar’s Vertex N 720W Series of n-type tunnel oxide passivated contact (TOPCon) modules.

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Moderna and Vertex Pharmaceuticals, two of the biggest biotechnology companies in Massachusetts by head count, will together receive more than $11 million in tax breaks from the state in exchange ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...